Table 1 Key studies of TNF-blocker therapy in rheumatoid arthritis, 52-week follow-up
Therapy | Disease stage | Reference | Primary outcome | Radiologic outcome |
|---|---|---|---|---|
Infliximab | RA | Smolen and colleagues [16] | ACR20 | Modified TSS |
Infliximab | Early RA | Smolen and colleagues [17] | ACR20 | Modified TSS |
Etanercept | Early RA | Bathon and colleagues [18] | ACR20 | TSS |
Etanercept | RA | Klareskog and colleagues [19] | ACR20 | Modified TSS |
Etanercept | Early RA | Kekow and colleagues [20] | ACR20 | Modified TSS |
Adalimumab | Early RA | Breedveld and colleagues [21] | ACR50 | Modified TSS |
Adalimumab | RA | Keystone and colleagues [22] | ACR20 | Modified TSS |
Golimumab | RA | Kremer and colleagues [23] | ACR50 | Modified TSS |
Certolizumab | RA | Keystone and colleagues [24] | ACR20 | Modified TSS |